Evidence map›Paper›PMID 35202449›Full record

ArticlePLoS pathogens2022

Vaccinia virus D10 has broad decapping activity that is regulated by mRNA splicing.

Michael Ly, Hannah M Burgess, Sahil B Shah, Ian Mohr, Britt A Glaunsinger

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Ribosomes in poxvirus infection.Current opinion in virology · 2022
    Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Michael LyDepartment of Molecular and Cell Biology, University of California Berkeley, Berkeley, California, United States of America.
Hannah M BurgessDepartment of Microbiology, New York University School of Medicine, New York, New York, United States of America.
Sahil B ShahCenter for Computational Biology, University of California Berkeley, Berkeley, California, United States of America.
Ian MohrDepartment of Microbiology, New York University School of Medicine, New York, New York, United States of America.
Britt A GlaunsingerDepartment of Molecular and Cell Biology, University of California Berkeley, Berkeley, California, United States of America.ORCID 0000-0003-0479-9377
New York University · USUniversity of California, Berkeley · USHoward Hughes Medical Institute · US

Funding

GENOMICST32HG000047 · NHGRI · UNIVERSITY OF CALIFORNIA BERKELEY · PI RASMUS NIELSEN, Daniel Soleyman Rokhsar · 2000 to 2026
$13.5M
Control of Translation in Herpesvirus Infected Cells - Resubmission - 1R01GM056927 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Ian J Mohr · 1999 to 2026
$7.6M
Disruption of Cellular RNA Processing by Kaposi's Sarcoma-Associated HerpesvirusR01CA136367 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI Britt A Glaunsinger · 2010 to 2026
$5.8M
Virus Host Interactions that Regulate Translation in Cells Infected with HSV-1R01AI073898 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MOHR, IAN J · 2008 to 2020
$5.0M
EPITRANSCRIPTOMIC REGULATION OF CYTOMEGALOVIRUS INFECTIONR01AI152543 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DEPLEDGE, DANIEL PEARCE, MOHR, IAN J · 2020 to 2025
$2.7M
Control of antiviral immunity by RNA decayR21AI126102 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MOHR, IAN J · 2016 to 2017
$466k
Cellular RNAs in anti-viral immunity to HSV1 - Resubmission - 1R21AI151436 · NIAID · UNIVERSITY OF SURREY · PI BURGESS, HANNAH MARION · 2021 to 2022
$389k
Circular RNAs in HSV1 infection and antiviral immunityR21AI166638 · NIAID · UNIVERSITY OF SURREY · PI BURGESS, HANNAH MARION · 2021 to 2022
$194k
NCI NIH HHS R01 CA136367NHGRI NIH HHS T32 HG000047NIAID NIH HHS R01 AI073898NIAID NIH HHS R01 AI152543NIAID NIH HHS R21 AI126102NIAID NIH HHS R21 AI151436NIAID NIH HHS R21 AI166638NIGMS NIH HHS R01 GM056927
6 · The paper itself

Abstract

The mRNA 5' cap structure serves both to protect transcripts from degradation and promote their translation. Cap removal is thus an integral component of mRNA turnover that is carried out by cellular decapping enzymes, whose activity is tightly regulated and coupled to other stages of the mRNA decay pathway. The poxvirus vaccinia virus (VACV) encodes its own decapping enzymes, D9 and D10, that act on cellular and viral mRNA, but may be regulated differently than their cellular counterparts. Here, we evaluated the targeting potential of these viral enzymes using RNA sequencing from cells infected with wild-type and decapping mutant versions of VACV as well as in uninfected cells expressing D10. We found that D9 and D10 target an overlapping subset of viral transcripts but that D10 plays a dominant role in depleting the vast majority of human transcripts, although not in an indiscriminate manner. Unexpectedly, the splicing architecture of a gene influences how robustly its corresponding transcript is targeted by D10, as transcripts derived from intronless genes are less susceptible to enzymatic decapping by D10. As all VACV genes are intronless, preferential decapping of transcripts from intron-containing genes provides an unanticipated mechanism for the virus to disproportionately deplete host transcripts and remodel the infected cell transcriptome.

Indexed as

PoxviridaeVaccinia virusEndoribonucleasesHumansRNA CapsRNA, MessengerViral ProteinsEndoribonucleasesRNA CapsRNA, MessengerViral Proteins

Identifiers

PMID35202449
PMCPMC8903303
OpenAlexW4221005328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.